Is Aligos Therapeutics, Inc. ALGS stock Halal to invest in?

No, as of September 2026, Aligos Therapeutics, Inc. stock (ALGS) is not currently classified as a Shariah compliant stock. This verdict follows the screening methodology of AAOIFI (the Accounting and Auditing Organization for Islamic Financial Institutions), whose Shariah Standard No. 21 is the leading global benchmark for screening Halal stocks. To qualify as Halal under this standard, a company must keep non-permissible income below 5% of total revenue, keep both interest-bearing investments and interest-bearing debt below 30% of market capitalisation, and have no impermissible preference share structure. Aligos Therapeutics, Inc. currently does not meet the threshold for the interest-bearing investments screen. Because screenings are refreshed monthly as new financial reports are published, a non-compliant stock can regain compliant status if its financial structure changes. You can track the latest status of Aligos Therapeutics, Inc. and discover Shariah compliant alternatives among the Halal stocks in the Tabadulat app.

How often is Aligos Therapeutics, Inc. ALGS reviewed for Shariah compliance?

Tabadulat reviews Aligos Therapeutics, Inc. ALGS for Shariah compliance every month. Each review applies the AAOIFI Shariah Standard No. 21 methodology, screening the company's business activities, non-permissible income, interest-bearing investments, interest-bearing debt, and preference shares, against the company's latest available financial data. The process operates under the direct supervision of Tabadulat's dedicated Shariah Supervisory Board of Islamic finance scholars. Because compliance depends on financial ratios that move with market capitalisation and reported results, a stock's status can change from one review to the next. Monthly screening ensures the status shown for Aligos Therapeutics, Inc. reflects current financial data rather than an outdated assessment, and Tabadulat app users are notified if a holding in their portfolio becomes non-compliant.

Does Aligos Therapeutics, Inc. ALGS pass the AAOIFI Non Permissible Income criteria?

Yes, as of September 2026, Aligos Therapeutics, Inc. stock (ALGS) passes the AAOIFI non-permissible income screen. In practice this screen asks a simple question: how much of the company's revenue comes from sources Islam prohibits, such as Riba, conventional financial services, alcohol, gambling or tobacco? AAOIFI allows at most 5%, and Aligos Therapeutics, Inc. stays below that line this month. Even permissible levels of incidental impure income should still be purified: investors donate the corresponding share of dividends to charity, as reflected in the stock's purification factor. This screen is reassessed monthly using the company's latest financial disclosures.

Does Aligos Therapeutics, Inc. ALGS pass the AAOIFI Interest Bearing Investments criteria?

No, as of September 2026, Aligos Therapeutics, Inc. stock (ALGS) does not pass the AAOIFI interest-bearing investments screen. Under AAOIFI Shariah Standard No. 21, the cash a company places in interest-earning instruments (such as conventional deposits, bonds, treasury bills and money-market funds) must remain below 30% of its market capitalisation. Aligos Therapeutics, Inc.'s interest-bearing investments currently exceed this 30% limit, meaning too large a share of the company's value derives from Riba-based instruments for the stock to qualify as Halal on this criterion. The ratio moves with both the balance sheet and the share price, and is reassessed monthly.

Does Aligos Therapeutics, Inc. ALGS pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of September 2026, Aligos Therapeutics, Inc. stock (ALGS) passes the AAOIFI interest-bearing debt screen. Under AAOIFI Shariah Standard No. 21, a company's borrowings that accrue interest (conventional bank loans, bonds and similar Riba-based financing) must remain below 30% of its market capitalisation. This cap limits shareholders' exposure to interest-based leverage. Aligos Therapeutics, Inc.'s interest-bearing debt is currently within the 30% threshold. Because market capitalisation changes daily, a company's debt ratio can drift toward or away from the limit even without new borrowing, which is why this screen is reassessed every month.

What is the dividend purification factor for Aligos Therapeutics, Inc. ALGS stock?

Aligos Therapeutics, Inc. (ALGS) is currently classified as not Shariah compliant, so no dividend purification factor applies, because purification factors are calculated only for stocks that pass the AAOIFI screens. Purification (Tazkiyah) is the practice of donating to charity the small portion of dividend income that stems from incidental non-permissible sources, such as interest earned on a compliant company's cash deposits. For non-compliant stocks the issue is not purification but eligibility: under AAOIFI Shariah Standard No. 21 the stock does not currently qualify as a Halal investment. If Aligos Therapeutics, Inc. returns to compliance in a future monthly screening, its purification factor will be published alongside its updated status in the Tabadulat app.

Does Aligos Therapeutics, Inc. ALGS pass the AAOIFI Preference Share screen?

Yes, as of September 2026, Aligos Therapeutics, Inc. stock (ALGS) passes the AAOIFI preference share screen. AAOIFI Shariah Standard No. 21 prohibits investing in preference shares because they grant holders guaranteed or priority rights to dividends and capital ahead of ordinary shareholders, a structure that conflicts with the Shariah principle that investors should share profit and loss in proportion to their ownership. Aligos Therapeutics, Inc. has no impermissible preference share structure affecting its ordinary shares, so the stock is compliant on this criterion. Like all AAOIFI screens, this is verified in each monthly review.

Invest Halal, Anytime, Anywhere

Download the Tabadulat app and start building your Shariah-compliant portfolio in minutes.

English

العربية

Is Aligos Therapeutics (ALGS) stock Halal?

NASDAQ

Shariah-Compliant

Not Shariah

Aligos Therapeutics, Inc. (ALGS) is not Shariah compliant in the September 2026 AAOIFI screening: it fails the interest-bearing investments screen. Tabadulat re-screens ALGS monthly, and a stock can return to compliance when new financial reports change its ratios.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

Website:

https://www.aligos.com

Market cap:

$39M

P/E ratio:

Dividend yield:

52-week range:

$3.98 - $13.69

Data as of:

3 September 2026

Screening history:

September 2026: FAIL

Aligos Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of targeted antiviral and liver disease therapies. The firm focuses on unmet medical needs in chronic liver and viral diseases, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH), and coronavirus infections. Its pipeline includes innovative oral small molecule drug candidates such as Pevifoscorvir sodium, a capsid assembly modulator targeting chronic hepatitis B virus infection, and ALG-055009, a thyroid hormone receptor beta agonist for metabolic dysfunction-associated steatohepatitis. Before any of that matters to a Muslim investor, one question comes first: is Aligos Therapeutics stock Halal?

Is Aligos Therapeutics Shariah compliant?

The Shariah case on a technology company like Aligos Therapeutics is rarely about the product. What AAOIFI Shariah Standard No. 21 examines is the money around the product: cash parked in instruments that earn Riba, borrowing measured against a market capitalisation that moves daily, and any incidental income from sources Islam prohibits, which must stay below 5% of revenue.

Does Aligos Therapeutics pass the business activity test?

The activity screen is only part of the picture this month: Aligos Therapeutics currently fails the interest-bearing investments screen, so the overall verdict is not compliant regardless of the business itself. The watch item for technology names is incidental: cash returns and platform content can carry impermissible elements, which AAOIFI tolerates only below the thresholds.

Is Aligos Therapeutics' income Halal?

Yes, within AAOIFI's tolerance. Aligos Therapeutics' income from non-permissible sources stays below 5% of revenue in the September 2026 screening.

Does Aligos Therapeutics meet AAOIFI's debt and investment ratio requirements?

Not in full. Interest bearing investments currently exceed the 30% cap, while the other ratio stays within it. One breach is enough to fail the screening; the ratios are reassessed monthly under our Shariah Supervisory Board.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the four screens? Read Why a Halal Stock Screener Matters for Halal Investing

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Open your account.

Create your Tabadulat account in minutes: enter your details, complete identity verification, and add funds by secure transfer in multiple currencies. You're ready to start investing in Halal stocks the same day.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.